Forte Biosciences (FBRX) Cash & Equivalents (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Cash & Equivalents data on file, last reported at $58.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $58.2 million, up 26.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.2 million (up 26.97% YoY), and the FY2025 annual result was $77.0 million, up 245.97% from the prior year.
• Cash & Equivalents retreated to $58.2 million in Q1 2026 per FBRX's latest filing, from $77.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $106.1 million in Q2 2025 and troughed at $16.4 million in Q3 2024.
• A 5-year average of $45.7 million and a median of $40.0 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 64.5% in 2024, then jumped 469.51% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $41.1 million in 2022, then decreased by 9.67% to $37.1 million in 2023, then tumbled by 40.08% to $22.2 million in 2024, then surged by 245.97% to $77.0 million in 2025, then retreated by 24.34% to $58.2 million in 2026.
• Business Quant data shows FBRX's Cash & Equivalents at $58.2 million in Q1 2026, $77.0 million in Q4 2025, and $93.4 million in Q3 2025.